Language selection

Search

Patent 2176229 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2176229
(54) English Title: IMPROVED INTERFERON POLYMER CONJUGATES
(54) French Title: PRODUITS DE CONJUGAISON AMELIORES D'UN INTERFERON AVEC UN POLYMERE
Status: Expired
Bibliographic Data
(51) International Patent Classification (IPC):
  • A61K 47/48 (2006.01)
  • A61K 38/21 (2006.01)
  • C07K 14/56 (2006.01)
  • A61K 38/00 (2006.01)
(72) Inventors :
  • GILBERT, CARL W. (United States of America)
  • CHO, MYUNG-OK (United States of America)
(73) Owners :
  • ENZON, INC. (United States of America)
(71) Applicants :
  • ENZON, INC. (United States of America)
(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.
(74) Associate agent:
(45) Issued: 2003-05-27
(86) PCT Filing Date: 1994-11-10
(87) Open to Public Inspection: 1995-05-18
Examination requested: 1999-04-06
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/US1994/013207
(87) International Publication Number: WO1995/013090
(85) National Entry: 1996-05-09

(30) Application Priority Data:
Application No. Country/Territory Date
08/150,643 United States of America 1993-11-10

Abstracts

English Abstract






A process is disclosed for preparing long-acting alpha interferon-containing compositions. Alpha interferon is contacted with a
relatively small molar excess of a substantially non-antigenic polymer in the presence of a surfactant to preserve bioactivity. Isolation of
the desired conjugate species having optimal activity is also disclosed.


French Abstract

On décrit un procédé de préparation de compositions à effet prolongé contenant l'interféron alpha. L'interféron alpha est mis en contact avec un excès molaire relativement faible d'un polymère essentiellement non antigène, en présence d'un tensioactif, pour conserver la bioactivité. On décrit également une purification du produit de conjugaison pour obtenir un produit souhaité ayant une activité optimale.

Claims

Note: Claims are shown in the official language in which they were submitted.



-19-

WE CLAIM:

1. A process for preparing a long-acting alpha-interferon-containing
composition, comprising contacting an alpha interferon with from a 1 to an 8-
fold molar excess of an activated polyalkylene oxide containing an alkyl
terminal in the presence of a surfactant under conditions sufficient to form
canjugates of said alpha interferon and said polyalkylene oxide having an
alkyl terminal and thereafter fractionating the conjugates to isolate the
conjugates containing 1-4 polyalkylene oxide strands per alpha-interferon
molecule.

2. The process of claim 1, wherein said molar excess is from 1.5 to 7-fold.

3. The process of claim 2, wherein said molar excess is from 1.75 to 5-
fold.

4. The process of claim 1, wherein polyalkylene oxide containing said
alkyl terminal is a polyethylene glycol.

5. The process of claim 1, wherein said polyalkylene oxide is a
monomethyl-terminated polyethylene glycol, (mPEG).

6. The process of claim 5, wherein said mPEG is activated with
succinimidyl carbonate.

7. The process of claim 5, wherein said mPEG is activated with
succinimidyl succinate.

8. The process of claim 5, wherein said mPEG is activated with a
hydrazine moiety.


-20-

9. The process of claim 1, wherein said polyalkylene oxide polymer has a
molecular weight of from 200 to 35,000.

10. The process of claim 9, wherein said polyalkylene oxide polymer has a
molecular weight of from 1,000 to 15,000.

11. The process of claim 10, wherein said polyalkylene oxide polymer has
a molecular weight of from 2,000 to 12,500.

12. The process of claim 1, wherein said surfactant is ionic.

13. The process of claim 12, wherein said surfactant comprises sodium
dodecyl sulfate (SDS).

14. The process of claim 12, wherein said surfactant is selected from the
group consisting of lithium dodecyl sulfate, quaternary ammonium
compounds, taurocholic acid, caprylic acid, decane sulfonic acid and mixtures
thereof.

15. The process of claim 12, wherein said surfactant is present in an
amount from 0.01-0.5%.

16. The process of claim 15, wherein said surfactant is present in an
amount of from 0.05 to 0.5%.

17. The process of claim 16, wherein said surfactant is present in an
amount of from 0.075 to 0.25%.

18. The process of claim 1, wherein said surfactant is selected from the
group consisting of polyoxyethylene sorbitans, polyoxyethylene ethers and
mixtures thereof.



-21-

19. The process of claim 1, further comprising separating the conjugated-
alpha interferon species containing from one to three polyalkylene oxide
strands.

20. The process of claim 19, further comprising separating the conjugated-
alpha interferon species containing two polyalkylene oxide strands.

21. The process of claim 1, wherein said alpha interferon is isolated from a
mammalian source.

22. The process of claim 21, wherein said alpha interferon is human alpha
interferon.

23. The process of claim 21, wherein said alpha interferon is ruminant
alpha interferon.

24. The process of claim 23, wherein said ruminant alpha interferon is
bovine alpha interferon.

25. The process of claim 21, wherein said alpha interferon is porcine alpha
interferon.

26. The process of claim 1, wherein said conjugates isolated after said
fractionating step contain 1-2 polyalkylene oxide strands per alpha interferon
molecule.

27. The process of claim 1, wherein said alpha-interferon is interferon
alpha 2b.

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 02176229 2002-03-28
_1_.
IMPROVED INTERFERON POLYMER CONJUGATES
BACKGROUND OF THE INVENTION
The present invention is directed to long-acting interferon-
containing preparations.
Conjugating biologically-active proteins to polymers has been
suggested to improve one or more of the properties of circulating life, water
solubility or antigenicity in vivo. For example, some of the initial concepts
of
coupling peptides or polypeptides to polyethylene glycol (PEG) and similar
water-soluble polymers are disclosed in U.S. Patent No. 4,179,337.
Insulin and hemoglobin were among the first therapeutic agents
conjugated. These relatively large polypeptides contain several free ~-amino
attachment sites. Several polymers could be attached without significant loss
of biologic activity.
The conjugation process, however, is not without complications.
Excessive polymer conjugation or reactions using molar excesses of polymers
beyond certain ratios have resulted in inactive conjugates. Problems often
result when a therapeutic moiety's active site (i.e. where groups associated
with bioactivity are found) becomes blocked by polymer attachment. This
problem can be difficult to avoid since the polymer and protein are typically
joined in solution-based reactions. Pre-blocking the active sites with
materials
such as pyridoxal phosphate have been suggested, but the results have been
inconsistent. The problems are particularly acute with lower molecular weight
proteins and peptides. These bioactive materials often have few attachment
sites not associated with bioactivity.
Interferons are a particular example of proteins which could
benefit from improved polymer conjugation techniques. See, for example,
U.S. Patent Nos. 4,760,106 and 4,917,888 which describe inter alia beta
interferon conjugated with methoxypolyethylene glycol N-succinimidyl



WO 95113090 217 6 2 2 9 PCTIUS94113207 0
2
glutarate or methoxypolyethylene glycol N-succinimidyl
succinate. The conjugation reactions were carried out using ,.
relatively high molar excesses (i0, 20 and 50-fold) of the
polymer.
European Patent Application bearing publication No. 0
236 987 describes reacting alpha and gamma interferons with
high molar excesses of alkyl imido ester-activated
polyethylene glycols. European Patent Application bearing
publication No. 0 510 356 describes conjugating alpha
interferon with pyridinyl carbonyl and thiocarbonyl
activated PEG. In both cases, the reactions were not
carried out in the presence of surfactants nor were the
conjugated species fractionated to isolate the most desired
conjugate species.
Inspite of the above-described disclosures, the
interferon-polymer conjugates have been unacceptable. One
of the chief drawbacks has been that the level of retained
interferon activity has been too low. Further, some
conjugation reactions have been too low-yielding to be
economical.
The present invention addresses these shortcomings.
F THE
One aspect of the invention provides a process for
preparing long-acting alpha-interferon-containing
compositions. The process includes contacting alpha-
interferon with a substantially non-antigenic polymer in
the presence of a surfactant under conditions which are
sufficient to effect conjugation of the protein and
polymer. Suitable alpha-interferons include recombinant
and alpha-interferons isolated from mammals.
The polymer portion of the conjugate is preferably a
polyalkylene oxide (PAO), such as mono-alkyl terminated
PAO's like mono-methyl polyethylene glycol (mPEG). The
non-alkyl-terminated end of the polymer is functionaliaed



W O 95113090 217 6 2 2 9 P~T~S94113207
3
with a reactive group capable of bonding with the alpha-


interferon, preferably at the epsilon (e) amino acid


lysines. The polymers may have a molecular weight of from


. about 200 to about 35,000. Other substantially non-


antigenic polymers can also be used.


The conditions for effecting conjugation include


conducting the reaction with a relatively small molar


excess of the polymer with respect to the alpha-interferon.


The range of molar excess for the polymer can be from about


1 to 8-fold; molar excesses of from about 1.5 to 7 are


preferred and a range of from about 1.75 - 5-fold are


particularly preferred.


The conditions further include contacting the


reactants in the presence of a surfactant which is present


in amounts ranging from about 0.1 to about 1% by weight.


One particularly preferred ionic surfactant is sodium


dodecyl sulfate (SDS). Other ionic and non-ionic


surfactants can also be used.


The resulting conjugates can have from about 0 to


about 6 polymeric strands attached to each alpha-interferon


molecule. After conjugation, those species containing


about 1-4 polymer strands per IFN and most preferably those


conjugates containing about 2 polymer strands per IFN


molecule are fractionated away from the other species.


The invention also includes methods of treating alpha-


interferon susceptible conditions in mammals. In this


aspect, treatment includes administering an effective


amount of the conjugates described herein to mammals


rerni?ring such therapy.


As a result of the present invention, highly active,


long lasting alpha-interferon-containing conjugates are


provided. In preferred embodiments, the isolated species


provide predictable, uniform activity.


For a better understanding of the present invention,


, reference is made to the following description.



CA 02176229 2002-03-28
-4-
DETAILED DESCRIPTION OF THE INVENTION
1. INTERFERONS
The alpha-interferon (a-IFN) portion of the polymer conjugate
can be prepared or obtained from a variety of sources including recombinant
techniques such as those using synthetic genes expressed in E. coli. See also
Pestka, "Interferon a" in Human Cytokines, Blackwell Scientific Publications 1-

16 (1992). In addition, the aIFN can also be a mammalian extract such as
human, ruminant or bovine aINF. One particularly preferred aIFN is INFa-2b,
a recombinantly-made product of the Schering Corp., Kenilworth, NJ.
Alternate embodiments, where the foreign aINF is not completely autologous,
may be used since the polymeric modification sufficiently reduces antigenic
responses.
A key, however, is that the non-autologous aIFN has sufficient
bioactivity or aIFN effect such as antiviral activity in the target mammal.
Other
substances including aIFN fractions or predecessor polypeptides can also be
included in the conjugates of the present invention. As used herein, "aIFN
effect in mammals" means any substance which demonstrates in viva activity
corresponding to that observed with cxIFN's. These substances are prepared
by using techniques known to those of ordinary skill in the art such as tissue
culture, extraction from animal sources or by recombinant DNA
methodologies. Transgenic sources of aIFN and related moieties are also
contemplated. Such materials are obtained from transgenic animals, i.e. mice,
pigs, cows, etc. where the aIFN pratein is expressed in milk, blood, or
tissues.
It is also understood that the recombinant techniques could also include a
glycosylation site for addition of a carbohydrate moiety on the recombinantly-
derived polypeptide. The method by which the aIFN is prepared for the
conjugates of the present

CA 02176229 2002-03-28
-5--
invention is not limited to those described herein.
aIFN has certain advantages over other interferon species such
as ~3 and y IFNs. For purposes of the present invention, the aIFN's are
preferred because of their biochemical and serological properties. In
particular, aIFN has documented antiviral properties and diffuses more
effectively into the bloodstream than other interferons. An important aspect
of
the present invention is the recognition that unlike other IFN's, aIFN has
three
lysines in active site area of the polypeptide. It has been surprisingly
determined that the attachment techniques described herein sufficiently
protect these lysines from polymeric attachment (and inactiviation) during
conjugation. As will be discussed below, most polymers attach at aIFN lysines
which are not associated with bioactivity.
2. NON-ANTIGENIC POLYMERS
To conjugate the aIFN to polymers such as poly(alkylene
oxides), one of the polymer hydroxyl end-groups is converted into a reactive
functional group which allows conjugation. This process is frequently referred
to as "activation" and the product is called "activated poly(alkylene oxide)".
Other substantially non-antigenic polymers are similarly "activated" or
functionalized.
The activated polymers are reacted with aIFN so that
attachment preferably occurs at ~-amino groups of lysines. Free carboxylic
arid groups, suitably activated carbonyl groups, oxidized carbohydrate
moieties and mercapto groups if available on the IFN can also be used as
attachment sites.
In a preferred aspect of the invention, urethane linkages are
formed between with the aIFN ~ amino groups and the activated polyalkylene
oxides. Preferably, the urethane linkage is formed as described in commonly
owned U.S. Patent No. 5,122,614.

CA 02176229 2002-03-28
-6-
This patent discloses the formation of N-succinimide carbonate derivatives of
polyalkylene oxides. Polymers activated with amide-forming linkers or the like
are also contemplated. Other functional groups which facilitate attchment of
the polymer to the IFN via c amino or other groups are also contemplated.
Among the substantially non-antigenic polymers, mono-
activated, alkyl-terminated polyalkylene oxides (PAO's), such as monomethyl-
terminated polyethylene glycols (mPEG's) are preferred; bis-activated
polyethylene oxides are also contemplated for purposes of cross-linking
aIFN's or providing a means for attaching other moieties such as targeting
agents for localizing the polymer aIFN conjugate in a particular area such as,
for example, the liver.
Suitable polymers will vary substantially by weight. Polymers
having molecular weights ranging from about 200 to about 35,000 are usually
selected for the purposes of the present invention. Molecular weights of from
about 1,000 to about 15,500 are preferred and 2000 to about 12,500 are
particularly preferred.
The polymeric substances included are also preferably water-
soluble at room temperature. A non-limiting list of such polymers include
polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or
polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and
block copolymers thereof, provided that the water solubility of the block
copolymers maintained. In addition to mPEG, C~_4 alkyl-terminated polymers
are also useful.
As an alternative to PAO-based polymers, effectively non-
antigenic materials such as dextran, polyvinyl pyrrolidones, polyacrylamides,
polyvinyl alcohols, carbohydrate-based polymers and the like can be used.
Those of ordinary skill in the art will realize that the foregoing list is
merely
illustrative and that all polymer

CA 02176229 2002-03-28
_ 7 _.
materials having the qualities described herein are contemplated. For
purposes of the present invention, "effectively non-antigenic" means all
materials understood in the art as being nontoxic and not eliciting an
appreciable immunogenic response in mammals.
3. SURFACTANTS
In one preferred aspect, the surfactants used in the processes of
the present invention are ionic-type agents. One particularly preferred agent
is
sodium dodecyl sulfate, (SDS). Other ionic surfactants such as lithium
dodecyl sulfate, quaternary ammonium compounds, taurocholic acid, caprylic
acid, decane sulfonic acid, etc can also be used. Non-ionic surfactants can
also be used. For example, materials such as polyoxethylene sorbitants
(TweensT""), polyoxyethylene ethers (TritonsT"") can be used. See also
Neugebauer, A Guide to the Properties and Uses of Detergents in Biology
and Biochemistry (1992) Calbiochem Corp. The only limitations on the type of
surfactant used in the processes of the invention are that they do not cause
substantial denaturation of the IFN and do not completely inhibit polymer
conjugation. The surfactants are present in the reaction mixtures in amounts
from about 0.01-0.5 %; preferably from 0.05-0.5 %; and most preferably from
about 0.075-0.25 %. Mixtures of the surfactants are also contemplated.
While applicants are not bound by theory, the surfactants are
thought to provide a temporary, reversible protecting system during the
polymer conjugation process. aIFN contains three lysines in the active site
region. This relatively positive-charged area of the polypeptide has been
found to undergo substantial polymer conjugation during solution-based
processes without some kind of protection. This results in substantial or
complete loss of bioactivity. The surfactants have been found to be



WO 95113090 217 6 2 2 9 PCTIUS94I13207
S
surprisingly effective in selectively discouraging polymer
conjugation in this area while allowing lysine-based ..
conjugation to proceed on other areas of the polypeptide.
4. REACTION CONDITIONS


Conjugation reactions, sometimes referred to as


PEGylation reactions, are -often carried out in solution


without regard to where the polymer will attach to the


protein. Such techniques however have proven to be


inadequate for conjugating aIFN. --As described above, it


has been determined that a key to maintaining bioactivity


is to substantially avoid including those lysines in the


active site in the polymer coupling process.


The processes of the present invention achieves this


goal by carrying out the conjugation reaction in the


presence of a surfactant with relatively small molar


excesses of the polymer with respect to the aIFN. The


process is carried out with about 1-S-fold molar excesses;


preferably about 1.5-7-fold molar excesses and most


preferably about 1.75-5-fold molar excesses. In an


alternative aspect of the invention, conjugation is


effected using-small molar excesses of activated polymer


without a surfactant.


The process preferably includes combining the aIFN in


solution with the surfactant prior to introducing the


activated polymer. The complete conjugation reaction can be


carried out at about room temperature, 20-25C. It is also


preferred that the coupling reaction be allowed to proceed


for rather short periods of time, i.e. 1-2 hours, before


quenching.


5. FRACTIONATION OF CONJUGATES
The inventive process produces conjugates having
varying degrees of polyalkylene oxide substitution.
. Residual unconjugated PAO's and aIFN can also be present.



WO 95!13090 217 6 2 2 9 P~T~S94113207
9
This mixture is typically in a reaction buffer containing


one or more of phosphate, chloride and bicarbonate anions.


The PAO, aIFN and conjugate mixture is preferably


.. fractionated in a buffer solution containing from about 1-


10 mg/ml PAO-aIFN conjugates. Suitable solutions have a


pH of from about 7.0 to about 9.0 and preferably from about


7.5 to about 8.5. The solutions preferably contain one or


more buffer salts selected from KC1, NaCl, K2HP0" KH,PO~,


Na,HP04, NaH2P0" NaHCO" NaBO" (NH,)ZCO, and glycine NaOH.


Sodium phosphate buffers are preferred.


Depending upon the reaction buffer, the PAO-~IFN


conjugate solution may first have to undergo buffer


exchange/ultrafiltration. For example, the PAO-aIFN


conjugate solution can be ultrafiltered across a low


molecular weight cut-off (10,000 to 30,000 dalton) membrane


which will also remove most surfactants as well.


The fractionation of the conjugates into desired


species is preferably carried out using an anion exchange


medium. Such media are capable of selectively binding those


PAO-aIFN conjugates having 1-4 PAO strands, excess PAO and


unmodified aIFN. This fractionation occurs since the ~IFN


molecules of various degrees of substitution will have


isoelectric points which vary in a somewhat predictable


fashion. For.example, the isoelectric point of aIFN is


determined by the number of available lysine residues


available on the surface of the protein. These lysine


residues also serve as the point of attachment of


polyalkylene oxide conjugates. Therefore, as the degree of


substitution of polyalkylene oxide increases, the


isoelectric point decreases, and the ability of the


conjugate to bind to an anion exchange resin weakens.


The use of strongly polar anion exchange resins are
especially preferred for the method of the present
; invention. For this reason, quaternary amine coated anion



WO 95/13090 ~ . 21 l 6 2 2 9 pGT~S94~13207
1d
exchange resins are utilized. The quaternary amine resin


may be coated onto either a polymeric or silica matrix;


however, polymeric matrices are preferred. A number of


tetramethylamine, or quaternary methylamine
anion exchan
e


,
g
..


resins are commercially available, coated onto the support


matrices. Included among the commercially available


quaternary anion exchange resins suitable for use with the


present invention - are Q-HD, QA TRISACRYL and


QMA-SPHEROSIL, quaternary amine resins coated onto a


polymer matrix, manufactured by IBF of Garenne, France, for


Sepracor of Marlborough, Massachusetts; TMAE650M
a


,


tetramethylamino ethyl resin coated onto a polymer matrix


,


manufactured by EM-Separators of. Gibbstown, New Jersey;


QAE550C, and SUPERQC, each a quaternary amine resin


coated onto a polymer matrix and manufactured by TosoHaas


of Montgomeryville, PA. QMA Accell, manufactured by


Millipore of Millford, MA and PEI resins manufactured by JT


Baker of Phillipsburg, NJ, may also be used.


The anion exchange resin is packed in the column and


equilibrated by conventional means. A buffer having the


same pH and osmolality as the conjugated aIFN solution is


used. The conjugate-containing solution is then adsorbed


onto the column. At the completion of the loading, a


gradient flow of an elution buffer with increasing salt


concentrations is applied to the column to elute the


desired fractions of polyalkylene oxide-conjugated aIFN.


The fractions are of essentially uniform molecular weight


and degree ofsubstitution.


Preferred polyalkylene oxide conjugate fractions have


1-4 polyalkylene oxide strands per aIFN molecule.


Preferably the fraction contains about 1-3 and most


preferable about 2 PAO strands per- aIFN molecule. The


elution buffer preferably contains one or more salts


selected from KCl, NaCl, K,HPO" KH,PO" Na,HPO" NaH,P04,


NaHCO" NaBO, and (NH,)ZCO,. These fractions are





WO 95/13090 217 6 2 2 9 P~~S94113207
1I
substantially free of other conjugates. Any unconjugated
species can then be backwashed from the column by
conventional techniques.
Techniques utilizing multiple isocratic steps of
increasing concentration can also be used. Multiple
isocratic elution steps of increasing concentration will
result in the sequential elution of PAO-aIFN conjugates.
The degree of polyalkylene oxide-conjugation within each
fraction will be substantially uniform. However, the
degree of polyalkylene oxide conjugation for each fraction
will decrease with elution time. Ion exchange purification
of PAO-aIFN conjugates can also be carried out with, for
example, a Q-HD Column from Sepracor along with a dilute
sodium phosphate solution (10 mM NaPO, ion). The sample is
washed with 10 mM NaPO,~ to remove any unreacted PAO and
thereafter a step gradient elution with NaCl is used.
Elution with 10 mM NaCl recovers fractions containing
conjugates with greater than 3 polymer strands PAO per IFN;
elution with 50 mM NaCl recovers conjugates containing 1-
2 strands; elution with 150 mM NaCl recovers unmodified
IFN.
The temperature range for elution is between about 4°C
and about 25°C. Preferably, elution is carried out at a
temperature of from about 6°C to about 22°C. The elution
of the PAO-aIFN fraction is detected by W absorbance at
254nm. Fraction collection. may be achieved through simple
time elution profiles. The preferred fractions can also be
pooled in the elution buffer.
6. ~THODS OF TREATME~1T
Another aspect of the present invention provides
methods of treatment for various medical conditions in
mammals. The methods include administering an effective
amount of aIFN-polymer conjugate which has been prepared as
described herein to a mammal in need of such treatment. The



W 0 95/13090 ~ 217 6 2 2 9 PCTIUS94113207
12
conjugates are useful for, among other things, treating


interferon-susceptible conditions or conditions which would .


respond positively or favorably as these terms are known in


the medical arts to interferon-based therapy. Thus,


without limitation, the interferon conjugates can be used


to treat conditions which would benefit from the inhibiting


replication of interferon-sensitive viruses. In addition,


the conjugates can be used to modify various immune


responses including inhibition of antibody response to


antigenic challenge, inhibition of hypersensitivity


reactions, regulation of NK cell activity enhancement of


cytotoxic T cell activity, modulate prostaglandin


production and enhance phagocytosis by macrophages.


Additional conditions in which the IFN-polymer


conjugates can be used include hairy cell leukemia,


venereal or genital warts (condylomata acuminata), AIDS-


Related Kaposi~s sarcoma, hepatitis and hepatitis-like


viral conditions including hepatitis-B and chronic


hepatitis non-A, non-B/C.


The amount of the a-IFN polymer conjugate administered


to treat the conditions described above is based on the IFN


activity of the polymeric conjugate. It is an amount that


is sufficient to significantly affect a positive clinical


response. The maximal dose for mammals including humans is


the highest dose that does not cause clinically-important


aide effects. For purposes of the present invention, such


clinically important side effects are those which would


require cessation of therapy due to severe flu-like


symptoms, central nervous system depression, severe


gastrointestinal disorders, alopecia, severe pruritus or


rash. Substantial white and/or red blood cell and/or liver


enzyme abnormalities or anemia-like conditions are also


dose limiting.


Naturally, the dosages of the various aIFN


. compositions will vary somewhat dependingupon the aIFN



CA 02176229 2002-03-28
-13-
moiety and polymer selected. In general, however, the conjugate is
administered in amounts ranging from about 100,000 to about several
million IU/m2 per day, based on the mammal's condition. The range set
forth above is illustrative and those skilled in the art will determine the
optimal dosing of the conjugate selected based on clinical experience and
the treatment indication.
The aIFN-polymer conjugates of the present invention can be
included in one or more suitable pharmaceutical compositions for
administration to mammals. The pharmaceutical compositions may be in
the form of a solution, suspension, tablet, capsule or the like, prepared
according to methods well known in the art. It is also contemplated that
administration of such compositions will be chiefly by the parenteral route
although oral or inhalation routes may also be used depending upon the
needs of the artisan.
EXAMPLES
The following examples serve to provide further appreciation of the
invention but are not meant in any way to restrict the effective scope of the
invention.
EXAMPLE 1
Preparation of raIFN-PEGSOOO in presence of SDS (0.1 %)
In this example, recombinant aIFN-2b, (raIFN), a product of the
Schering Corporation, Kenilworth, New Jersey was conjugated with
activated polyethylene glycol-N-succinimide carbonate (SC-PEG) as
described in U.S. patent No. 5,122,614. The polymer had a molecular
weight of about 5000.
36 mg of the raIFN was dialyzed into 0.1 molar sodium phosphate
pH 7.5 using a Gentricon-10TM (a product of the Amicon Corporation of
Beverly, Mass.). The final

CA 02176229 2002-03-28
-14-
concentration of raIFN was about 3 mg/ml. 0.1 ml of 10% SDS was added
to the raIFN and was allowed to incubate at room temperature for 10
minutes. Thereafter, 42 mg of SC-PEGSOOO was added to the protein-SDS
solution and stirred at room temperature for two hours and then quenched
with glycine. Next, the reaction mixture was dialyzed into 10 mM sodium
phosphate pH 8 to fractionate the PEGylated IFN using a Centricon-30TM
EXAMPLE 2
Preparation of raIFN-PEG~2ooo in presence of SDS (0.1 %)
In this Example, the steps of Example 1 were repeated except that
the polyethylene glycol had a molecular weight of about 12000. Reaction
steps were exactly the same to provide the PEG~2ooo conjugate.
EXAMPLE 3
Fractionation of 2PEG5oooraIFN
In this Example the conjugates prepared in accordance with
Example 1 were fractionated to obtain the desired 2-PEGSOOO fraction. The
PEG-aIFN in sodium phosphate buffer was loaded onto a QHDTM anion
exchange column. The 2-PEG fraction was eluted with a gradient from 0 to
400 mm sodium chloride in 10 Mm phosphate pH 8. The 2-PEG fraction
was verified with using size exclusion chromatography and SDS-Page.
EXAMPLE 4
Fractionation of 2PEG~2oooralFN
The polymer conjugates of Example 2 were fractionated in the
manner described in Example 3 and verified in the same manner.

CA 02176229 2002-03-28
-15-
EXAMPLES 6-8
In these examples, additional preparations of PEG~zoooraIFN were
prepared as described previously except that no surfactant was used. The
samples were tested for retained activity and PEG number. The results are
provided below in the table.
Table 1
ACTIVITY (CPE)


PREPARATION % OF CONTROL PEG #a


Example 6 - 26 1.2


Example 7 26 1.3


Example 8 24 1.0


a average number of PEG molecules per IFN
EXAMPLE 9
Comparative Data
In this example, the product of Example 3, (SDS-2-PEG5oooraIFN),
2-PEG5oooraIFN made in the absence of a surfactant and conjugated
raIFN were tested. Activity was determined using a CPE assay with EMC
virus challenging A54g human lung carcinoma cells. Circulating life was
determined using an average value obtained from the blood of 3 rats in a
group receiving 1 millian units, with time points taken over 7 days.
Table 2
VIRAL CIRCULATING


PROTECTION HALF LIFE


ACTIVITY ASSAY IC5o a PHASE


_. (/~_ _- /ml (HRS.)


A. I FN-SDS 6g 2.2 5.8


2-PEGSOOO __ __ _____ _
~


B. IFN-PEGsooo_ 30 4.0 6.8


C. IFN 100 1.5 0.17





WO 95/13090 ~2 1 7 6 2 2 9 PCTIU594113207
16
This data clearly shows the advantages of the
inventive process. Retained activity is over twice as great
as that obtained using standard technidues.
EBAbIPLE 10
In this example, various pharmacokinetic data was
generated using the various 2PEG-raIFN conjugates shown
below prepared according to the methods described above.
These samples were compared to unmodified IFN according to
the protocol set out in Table 3. Sample B was prepared
with SDS.
Table 3
~tetaiaed Activity
CP8 ACTIVITY
SAMPLE PEG MOLECULAR WEIGHT (% CONTROL)


A 5,000 35


B 5,000 69


C 12,000 26


D 12,000 26


For example:
T
Ph:4r~pcokanet~c Protoco~
ANIMALS: Sprague Dawley (3 rates/time point)
DOSE: 10x10' UN IFN/rat
ROUTE: Subcutaneous (S. C.)
DRUG: 2-PEG-IFNa's 5,000 and 12,000 mol. wt.
PEG
TIME POINTS: 0 min., 5 min., 15 mih., 30 min., 1
hr. , 2 hr. , 4 hr. , 8 hr. , 24 hr. , 48
hr., 5 days, and 7 days following drug
administration.
ASSAY: CPE Assay using serum samples in an EMC
virus and A549 human lung carcinoma.



WO 95113090 2 1 7 6 2 2 9 PC1'IUS94/13207
17
AUC = Area Under Curve, C~, Tll,a, T,l,a - all have
~ their generally ascribed meanings known to those of
ordinary skill.
Tables 5 aad 6
,a",~,n~~ of Pharmacokinetica Data for PEG-Taterferoas
ICso % CmaX


SAMPLE (pg/ml) ACTIVITY AUC (IU/ml)


NATIVE 1.52 pg/ml 100% 145,720 60,000


IFNa (N=6)


4.0 pg/ml 35% 348,920 24,433


A (N=3)


2.2 t 0.5 69% 351,037 -


B Pg/~(N=3)


5.8 t 2.2 26% 1,574,682 62,750


C pg/ml(N=3)


Table 6
T"" Tll, a PHASE T11, ~B PHASH
SAMPLE (HR) (H&) (HR)


NATIVE
IFNa 1 0.17 -


A 4 6.8 48



B 2-3 5.8 -


C 8 12.1 33


The foregoing data provide the following conclusions:
2-PEG-raIFN conjugates prepared with both 5,000 and
12,000 molecular weight have distinct advantages over
unmodified interferon in mammals. In the case of
subcutaneously administered compositions, T~ is


WO 95113090 2 1 l 6 2 2 9 p~BJS94113207 4
substantially increased by the conjugation of the protein
with about 2 PEG's. For chronic conditions, longer Tm~'s
are desirable and allow clinicians to space out recurring
administrations due to the lengthening of the duration of- ,.
effect. Even more unexpected, however, was the fact that
2-PEGl,ooo conjugates are able to unexpectedly increase AUC
by over 10-fold. This effect achieved by the additional
polymer weight was not proportional to the dramatic
increase in area under-the curve. Clearly, therapeutic
advantages are realized by this unexpected increase.

Representative Drawing

Sorry, the representative drawing for patent document number 2176229 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 2003-05-27
(86) PCT Filing Date 1994-11-10
(87) PCT Publication Date 1995-05-18
(85) National Entry 1996-05-09
Examination Requested 1999-04-06
(45) Issued 2003-05-27
Expired 2014-11-10

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Application Fee $0.00 1996-05-09
Maintenance Fee - Application - New Act 2 1996-11-11 $100.00 1996-05-09
Registration of a document - section 124 $0.00 1996-12-05
Maintenance Fee - Application - New Act 3 1997-11-10 $100.00 1997-09-10
Maintenance Fee - Application - New Act 4 1998-11-10 $100.00 1998-09-04
Request for Examination $400.00 1999-04-06
Maintenance Fee - Application - New Act 5 1999-11-10 $150.00 1999-11-10
Maintenance Fee - Application - New Act 6 2000-11-10 $150.00 2000-11-07
Maintenance Fee - Application - New Act 7 2001-11-12 $150.00 2001-10-16
Maintenance Fee - Application - New Act 8 2002-11-11 $150.00 2002-10-22
Final Fee $300.00 2003-03-05
Maintenance Fee - Patent - New Act 9 2003-11-10 $150.00 2003-10-22
Maintenance Fee - Patent - New Act 10 2004-11-10 $250.00 2004-10-20
Maintenance Fee - Patent - New Act 11 2005-11-10 $250.00 2005-10-18
Maintenance Fee - Patent - New Act 12 2006-11-10 $250.00 2006-10-17
Maintenance Fee - Patent - New Act 13 2007-11-12 $250.00 2007-10-17
Maintenance Fee - Patent - New Act 14 2008-11-10 $250.00 2008-10-27
Maintenance Fee - Patent - New Act 15 2009-11-10 $450.00 2009-10-23
Maintenance Fee - Patent - New Act 16 2010-11-10 $450.00 2010-10-18
Maintenance Fee - Patent - New Act 17 2011-11-10 $450.00 2011-10-19
Maintenance Fee - Patent - New Act 18 2012-11-13 $450.00 2012-10-17
Maintenance Fee - Patent - New Act 19 2013-11-12 $450.00 2013-10-15
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
ENZON, INC.
Past Owners on Record
CHO, MYUNG-OK
GILBERT, CARL W.
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 2003-04-24 1 27
Abstract 2003-05-26 1 26
Description 2003-05-26 18 636
Claims 2002-09-06 3 85
Claims 1999-05-03 2 68
Cover Page 1996-08-19 1 11
Abstract 1995-05-18 1 26
Description 1995-05-18 18 554
Claims 1995-05-18 2 47
Claims 2002-03-28 3 89
Description 2002-03-28 18 636
Fees 1999-11-10 1 48
Correspondence 2003-03-05 1 39
Assignment 1996-05-09 10 339
PCT 1996-05-09 13 447
Prosecution-Amendment 1999-04-06 1 48
Fees 1998-09-04 1 49
Fees 2002-10-22 1 35
Fees 2001-10-16 1 31
Prosecution-Amendment 2002-09-06 4 119
Prosecution-Amendment 2001-09-28 2 54
Prosecution-Amendment 2002-03-28 13 525
Prosecution-Amendment 2002-06-17 2 44
Fees 1997-09-10 1 53
Fees 2000-11-07 1 34
Correspondence 2012-10-29 1 21
Correspondence 2013-04-09 2 70
Correspondence 2013-04-18 1 16
Fees 1996-05-09 1 48